University of Rochester Clinical Site within the NEXT Network of Clinical Trials

罗切斯特大学及其神经科学研究人员在神经系统疾病的实验治疗方面有着悠久而富有成效的记录。2011年，UR是入选美国国立卫生研究院（nih）资助的神经科学临床试验卓越网络（NeuroNEXT）的首批25个临床站点之一。UR的临床站点（UR- next）通过参与9项资助研究中的6项，积极参与网络运营，达到或超过许多试验性能指标，并在整个网络中分享我们独特的专业知识，为网络的成功和活力做出了贡献。泌尿外科是纽约州西部和北部主要的神经系统护理提供者，其转诊网络不断扩大，覆盖地区、国家和国际。UR-NEXT网站资源包括罗彻斯特大学临床和转化科学研究所、临床试验协调中心、健康+技术中心，以及我们的T32实验治疗学培训计划，现在已经连续资助了28年。UR-NEXT将继续是一个强大的卓越临床试验中心，允许灵活、高效和高度完整地实施NeuroNEXT和其他nind资助的临床试验，用于广泛的神经系统疾病的治疗开发。我们将通过以下方式进一步提升我们的能力：1)扩大我们在实验治疗方面具有特殊专业知识的杰出合作研究者队伍；2)传播我们的开发能力和技术，以提高NeuroNEXT和其他NINDS研究的试验效率；3)实施招聘增强程序，以加强和扩大社区伙伴关系。4)通过扩大内部指标并与临床与转化科学奖（CTSA）试验创新网络合作，加强我们的绩效改进和试验质量程序；5)开发职业提升计划，在四个专业领域培训初级教师，包括使能技术、罕见疾病、结果评估、先进设计和疾病建模。因此，UR-NEXT将继续为NeuroNEXT的目标做出强有力的贡献，即开展更好、更快、更有效的治疗研究，以帮助受神经系统疾病影响的患者和家庭。

The University of Rochester (UR) and its neuroscience investigators have a long and productive record in the experimental therapeutics of neurological disorders. In 2011, the UR was one of the original 25 Clinical Sites chosen to participate in the NIH-sponsored Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). The UR's Clinical Site (UR-NEXT) has contributed to the success and vitality of the Network by participating in 6 of 9 funded studies, being actively engaged in Network operations, performing at or above many trial performance metrics, and sharing our unique expertise throughout the Network. The UR is the dominant provider of neurological care in Western and Upstate New York with growing referral networks that have regional, national, and international reach. UR-NEXT site resources include the University of Rochester's Clinical and Translational Science Institute, the Clinical Trials Coordination Center, the Center for Health + Technology, and our T32 Training Program in Experimental Therapeutics, now in its 28th year of continuous funding. UR-NEXT will remain a powerful clinical trial center of excellence that allows for nimble, efficient, and high integrity implementation of NeuroNEXT and other NINDS-sponsored clinical trials for therapeutic development across a wide range of neurological diseases. We will further our abilities to be an exemplary clinical trial site by 1) expanding our cadre of exceptional co-investigators with special expertise in experimental therapeutics, 2) disseminating our developing capabilities and technologies to improve trial efficiency across NeuroNEXT and other NINDS studies, 3) implementing recruitment enhancement procedures to strengthen and expand community partnerships, 4) enhancing our performance improvement and trial quality procedures by expanding internal metrics and collaborating with the Clinical and Translational Science Award (CTSA) Trial Innovation Network, and 5) developing a Career Enhancement Program that trains junior faculty in four areas of specialization, including enabling technologies, rare diseases, outcomes assessment, and advanced design and disease modeling. As a result, UR-NEXT will continue as a strong contributor to NeuroNEXT's objectives to conduct therapeutic research that is better, faster, and more efficient in the quest to aid patients and families affected by neurological disease.